UCB Group presented its latest commercial and pipeline updates Wednesday during a J.P. Morgan European Healthcare CEO Call Series, reaffirming that its five identified growth drivers are performing according to plan and pointing to continued expansion through the decade.
Shares of UCB traded at EUR 211.60 on September 23, down EUR 1.90 or 0.89%, with a price-to-earnings ratio of 11.09 and a debt-to-equity ratio of 0.33, according to InvestingPro data.
Chief Executive Officer Jean-Christophe Tellier described the company as "entering into this period of growth," noting that the pipeline and commercial portfolio are on track. UCB completed four acquisitions during the year, including cell-therapy developer Neurona Therapeutics and T-cell engager candidate Candid Therapeutics.
Neurona's investigational cell therapy for mesial temporal lobe epilepsy is expected to enter Phase III trials in early 2026, while Candid's cizutamig — a BCMA/CD3 bispecific T-cell engager — continues development. UCB also advanced other candidates, including remibrutinib and leukocizumab, as part of a broader push across inflammatory and immune-mediated diseases.
In atopic dermatitis, galvokimig showed a 43% placebo-adjusted EASI 90 response rate in Phase IIa data, outperforming the 26% rate associated with rival dupilumab, according to context provided during the call. UCB also noted upcoming 2027 formulary discussions that could influence market access for its existing and emerging therapies.
For palmoplantar pustulosis, recruitment for a Phase III trial began in November 2025, with top-line data expected in 2028. Tellier also addressed hidradenitis suppurativa, emphasizing that the disease requires a distinct therapeutic approach compared with psoriasis.
On the competitive front, Tellier declined to comment on rivals' clinical programs beyond their published data. "If someone wants to do a Phase III — which we have done ourselves, demonstrating superior value — they are very welcome to do a superiority clinical trial," he said.
Looking further ahead, Tellier framed UCB's growth outlook across the next decade, citing protected revenue streams extending beyond 2030 and 2035, with BIMZELX — now treated by approximately 150,000 patients — holding marketplace access at roughly 80% across major indications and retaining patent exclusivity through 2037.
